New Cardiovascular Biomarkers in Patients with Advanced Cancer – A Prospective Study Comparing MR-proADM, MR-proANP, Copeptin, High-Sensitivity Troponin T and NT-proBNP
European Journal of Heart Failure · 2025
DOI: 10.1002/ejhf.3497 ↗Kurz gefasst
Vergleichsstudie in der Zeitschrift European Journal of Heart Failure, 2025. Verfasst von Markus S Anker und 18 weiteren Autor:innen. Beteiligte Einrichtung: Charité - University Medicine Berlin corporate member of Free University Berlin, and Humboldt-University Berlin, Berlin, Germany. Hauptthemen laut MEDLINE: Neoplasms, Glycopeptides, Peptide Fragments, Adrenomedullin. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 34 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: German Center for Cardiovascular Research, German Heart Foundation/German Foundation of Heart Research, Deutsche Herzstiftung.
Abstract (Originalsprache)
Aims
Traditional cardiovascular (CV) biomarkers (high-sensitivity troponinT [hsTnT] and N-terminal pro-B-type natriuretic peptide [NT-proBNP]) are important to monitor cancer patients' cardiac function and to assess prognosis. Newer CV biomarkers (mid-regional pro-adrenomedullin [MR-proADM], C-terminal pro-arginine vasopressin [copeptin], and mid-regional pro-atrial natriuretic peptide [MR-proANP]) might outperform traditional biomarkers. Methods and results Overall, 442 hospitalized cancer patients without significant CV disease or current infection were enrolled (61 ± 15 years, 52% male, advanced cancer stage: 85%) and concentrations of CV biomarkers were analysed. Differences in echocardiographic, clinical, laboratory parameters were assessed. Patients were followed for up to 69 months for all-cause mortality. In univariable analyses, MR-proADM, hsTnT, copeptin, MR-proANP, and NT-proBNP predicted all-cause mortality. In multivariable analyses (adjusted for sex, age, Eastern Cooperative Oncology Group performance status, estimated glomerular filtration rate [eGFR], C-reactive protein, anti-cancer therapy, reason for hospitalization, cancer stage and type), only MR-proADM remained an independent predictor of mortality (MR-proADM per 1 ln: hazard ratio [HR] 2.27, 95% confidence interval [CI] 1.47–3.50], p < 0.001). MR-proADM had the highest area under the curve (AUC) using receiver operating characteristic analysis (AUC [95% CI] 0.74 [0.69–0.79]; hsTnT: AUC 0.69; copeptin: AUC 0.66; MR-proANP: AUC 0.63; NT-proBNP: AUC 0.62). Optimal cut-point for mortality prediction with MR-proADM was 0.94 nmol/L (HR 2.43 [95% CI 1.92–3.06], p < 0.001). Patients with MR-proADM >0.94 nmol/L were older, more often had cancer stage IV, showed reduced performance status, eGFR, haemoglobin, diastolic left ventricular function, and elevated systolic pulmonary artery pressure.
Conclusion
MR-proADM is an independent predictor of mortality in advanced stage, hospitalized cancer patients without significant CV disease or current infection. The optimal MR-proADM cut-point for mortality prediction was 0.94 nmol/L with hazards for mortality being approximately 2.5 times higher. There was a continuous increase in mortality risk with stepwise increase of MR-proADM concentrations. Elevated concentrations of MR-proADM were also associated with reduced performance status and mildly reduced left ventricular diastolic function as well as higher age and more often cancer stage IV.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Charité - University Medicine Berlin corporate member of Free University Berlin, and Humboldt-University Berlin, Berlin, Germany.
- German Centre for Cardiovascular Research (DZHK), partner site Berlin, Berlin, Germany.
- Berlin Institute of Health Center for Regenerative Therapies (BCRT), Berlin, Germany.
- Department of Cardiology, Angiology and Intensive Care Medicine, Campus Benjamin Franklin, German Heart Center Charité, Berlin, Germany.
- Department of Cardiology, Angiology and Intensive Care Medicine, Campus Virchow Clinic, German Heart Center Charité, Berlin, Germany.
- Division of Cardiology, Duke University Medical Center, Durham, NC, USA.
ORCID-Profile: Markus S Anker
Förderung
- German Center for Cardiovascular Research
- German Heart Foundation/German Foundation of Heart Research
- Deutsche Herzstiftung
Zitieren
APA
Anker, M. S., Lück, L. C., Khan, M. S., Porthun, J., Hadzibegovic, S., Lena, A., Wilkenshoff, U., Weinländer, P., Evertz, R., Totzeck, M., Mahabadi, A. A., Rassaf, T., Anker, S. D., Bullinger, L., Keller, U., Karakas, M., Landmesser, U., Butler, J., & von Haehling, S. (2025). New Cardiovascular Biomarkers in Patients with Advanced Cancer – A Prospective Study Comparing MR-proADM, MR-proANP, Copeptin, High-Sensitivity Troponin T and NT-proBNP. European Journal of Heart Failure. https://doi.org/10.1002/ejhf.3497
Vancouver
Anker MS, Lück LC, Khan MS, Porthun J, Hadzibegovic S, Lena A, et al. New Cardiovascular Biomarkers in Patients with Advanced Cancer – A Prospective Study Comparing MR-proADM, MR-proANP, Copeptin, High-Sensitivity Troponin T and NT-proBNP. European Journal of Heart Failure. 2025. doi:10.1002/ejhf.3497
BibTeX
@article{Anker2025,
author = {Anker, Markus S and Lück, Laura C and Khan, Muhammad Shahzeb and Porthun, Jan and Hadzibegovic, Sara and Lena, Alessia and Wilkenshoff, Ursula and Weinländer, Pia and Evertz, Ruben and Totzeck, Matthias and Mahabadi, Amir A and Rassaf, Tienush and Anker, Stefan D and Bullinger, Lars and Keller, Ulrich and Karakas, Mahir and Landmesser, Ulf and Butler, Javed and von Haehling, Stephan},
title = {New Cardiovascular Biomarkers in Patients with Advanced Cancer – A Prospective Study Comparing MR-proADM, MR-proANP, Copeptin, High-Sensitivity Troponin T and NT-proBNP},
journal = {European Journal of Heart Failure},
year = {2025},
doi = {10.1002/ejhf.3497}
}
EUVIMED